First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
Month: July 2023
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
Lexicon Elects Diane E. Sullivan to Board of Directors
Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board…
Lexicon Elects Diane E. Sullivan to Board of Directors
Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board…
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume
Customer Cash Receipts (A$’000) Customer Cash Receipts (A$’000) MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE)…
Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume
Customer Cash Receipts (A$’000) Customer Cash Receipts (A$’000) MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE)…
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that…
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that…
Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform
The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new…
Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform
The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new…
Press release: Online availability of Sanofi’s half-year financial report for 2023
Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces…
Press release: Online availability of Sanofi’s half-year financial report for 2023
Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces…
Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
Biogen to Acquire Reata Pharmaceuticals
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia …
Biogen to Acquire Reata Pharmaceuticals
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia …
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center,…
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center,…